$7.11
-0.30-4.05%
Últ. Act.: Oct 30, 12:34 PM
Regenxbio (RGNX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.12 | $-1.40 | $-0.91 | $-1.33 |
| Actual | $0.43 | $-1.72 | $-1.30 | $-1.20 |
| Surprise | +258.3% | -22.9% | -42.9% | +9.77% |
| Revenue | ||||
| Estimate | $104.1M | $25.0M | $39.9M | $24.3M |
| Actual | $108.0M | $6.4M | $30.3M | $29.7M |
| Surprise | +3.76% | -74.4% | -23.9% | +22.6% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.31 | $-1.01 | $-1.04 | $-0.98 |
| Revenue | ||||
| Consensus | $14.5M | $32.6M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $0.43 | $0.12 | 258.3 % |
| Q1 | May 14, 2026 | $-1.72 | $-1.40 | -22.9 % |
| Q4 | Mar 5, 2026 | $-1.30 | $-0.91 | -42.9 % |
| Q3 | Nov 6, 2025 | $-1.20 | $-1.33 | 9.77 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $108.02M | $104.10M | 3.76 % |
| Q1 | May 14, 2026 | $6.39M | $24.96M | -74.4 % |
| Q4 | Mar 5, 2026 | $30.34M | $39.88M | -23.9 % |
| Q3 | Nov 6, 2025 | $29.73M | $24.26M | 22.6 % |